Migraine Drugs Market In Latin America 2026-2030

Publisher TechNavio

Published Jan 12, 2026

Length 207 Pages

SKU # INF20708828

Description

Migraine Drugs Market In Latin America 2026-2030

The migraine drugs market in latin america is forecasted to grow by USD 90.1 mn during 2025-2030, accelerating at a CAGR of 5.5% during the forecast period. The report on the migraine drugs market in latin america provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by escalating disease prevalence and heightened public awareness, modernization and infrastructure development, technological innovation and rise in biological therapies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
Technavio's migraine drugs market in latin america is segmented as below:

By Therapy

Preventive treatment
Abortive treatment

By End-User

Hospitals
Retail
Online

By Route Of Administration

Oral
Injectable
Nasal

Geography

Latin America

This study identifies the proliferation of calcitonin gene-related peptide antagonists and targeted biologics as one of the prime reasons driving the migraine drugs market in latin america growth during the next few years. Also, integration of digital health ecosystems and personalized telemedicine and increased awareness through who initiatives and local programs will lead to sizable demand in the market.

The report on the migraine drugs market in latin america covers the following areas:

Migraine drugs market in latin america sizing
Migraine drugs market in latin america forecast
Migraine drugs market in latin america industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading migraine drugs market in latin america vendors that include AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck A/S, Kowa Co. Ltd., Mallinckrodt Plc, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Ltd., UCB SA. Also, the migraine drugs market in latin america analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

1 Executive Summary
1 Executive Summary: 1.1 Market overview; Executive Summary - Chart on Market Overview; Executive Summary - Data Table on Market Overview; Executive Summary - Chart on Country Market Characteristics; Executive Summary - Chart on Market by Geography; Executive Summary - Chart on Market Segmentation by Therapy; Executive Summary - Chart on Market Segmentation by End-user; Executive Summary - Chart on Market Segmentation by Route of Administration; Executive Summary - Chart on Incremental Growth; Executive Summary - Data Table on Incremental Growth; Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
2 Technavio Analysis: 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; 2.2 Criticality of inputs and Factors of differentiation; Overview on criticality of inputs and factors of differentiation; 2.3 Factors of disruption; Overview on factors of disruption; 2.4 Impact of drivers and challenges; Impact of drivers and challenges in 2025 and 2030
3 Market Landscape
3 Market Landscape: 3.1 Market ecosystem; Chart on Parent Market; Data Table on - Parent Market; 3.2 Market characteristics; Chart on Market characteristics analysis; 3.3 Value chain analysis; Chart on Value chain analysis
4 Market Sizing
4 Market Sizing: 4.1 Market definition; Data Table on Offerings of companies included in the market definition; 4.2 Market segment analysis; Market segments; 4.3 Market size 2025; 4.4 Market outlook: Forecast for 2025-2030; Chart on Latin America - Market size and forecast 2025-2030 ($ million); Data Table on Regional - Market size and forecast 2025-2030 ($ million); Chart on Latin America: Year-over-year growth 2025-2030 (%); Data Table on Regional - Market size and forecast 2025-2030 ($ million)
5 Historic Market Size
5 Historic Market Size: 5.1 Migraine Drugs Market in Latin America 2020 - 2024; Historic Market Size - Data Table on Migraine Drugs Market in Latin America 2020 - 2024 ($ million); 5.2 Therapy segment analysis 2020 - 2024; Historic Market Size - Therapy Segment 2020 - 2024 ($ million); 5.3 End-user segment analysis 2020 - 2024; Historic Market Size - End-user Segment 2020 - 2024 ($ million); 5.4 Route of Administration segment analysis 2020 - 2024; Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million); 5.5 Geography segment analysis 2020 - 2024; Historic Market Size - Geography Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
6 Qualitative Analysis: 6.1 The AI impact on Migraine Drugs Market in Latin America
7 Five Forces Analysis
7 Five Forces Analysis: 7.1 Five forces summary; Five forces analysis - Comparison between 2025 and 2030; 7.2 Bargaining power of buyers; Bargaining power of buyers - Impact of key factors 2025 and 2030; 7.3 Bargaining power of suppliers; Bargaining power of suppliers - Impact of key factors in 2025 and 2030; 7.4 Threat of new entrants; Threat of new entrants - Impact of key factors in 2025 and 2030; 7.5 Threat of substitutes; Threat of substitutes - Impact of key factors in 2025 and 2030; 7.6 Threat of rivalry; Threat of rivalry - Impact of key factors in 2025 and 2030; 7.7 Market condition; Chart on Market condition - Five forces 2025 and 2030
8 Market Segmentation by Therapy
8 Market Segmentation by Therapy: 8.1 Market segments; Chart on Therapy - Market share 2025-2030 (%); Data Table on Therapy - Market share 2025-2030 (%); 8.2 Comparison by Therapy; Chart on Comparison by Therapy; Data Table on Comparison by Therapy; 8.3 Preventive treatment - Market size and forecast 2025-2030; Chart on Preventive treatment - Market size and forecast 2025-2030 ($ million); Data Table on Preventive treatment - Market size and forecast 2025-2030 ($ million); Chart on Preventive treatment - Year-over-year growth 2025-2030 (%); Data Table on Preventive treatment - Year-over-year growth 2025-2030 (%); 8.4 Abortive treatment - Market size and forecast 2025-2030; Chart on Abortive treatment - Market size and forecast 2025-2030 ($ million); Data Table on Abortive treatment - Market size and forecast 2025-2030 ($ million); Chart on Abortive treatment - Year-over-year growth 2025-2030 (%); Data Table on Abortive treatment - Year-over-year growth 2025-2030 (%); 8.5 Market opportunity by Therapy; Market opportunity by Therapy ($ million); Data Table on Market opportunity by Therapy ($ million)
9 Market Segmentation by End-user
9 Market Segmentation by End-user: 9.1 Market segments; Chart on End-user - Market share 2025-2030 (%); Data Table on End-user - Market share 2025-2030 (%); 9.2 Comparison by End-user; Chart on Comparison by End-user; Data Table on Comparison by End-user; 9.3 Hospitals - Market size and forecast 2025-2030; Chart on Hospitals - Market size and forecast 2025-2030 ($ million); Data Table on Hospitals - Market size and forecast 2025-2030 ($ million); Chart on Hospitals - Year-over-year growth 2025-2030 (%); Data Table on Hospitals - Year-over-year growth 2025-2030 (%); 9.4 Retail - Market size and forecast 2025-2030; Chart on Retail - Market size and forecast 2025-2030 ($ million); Data Table on Retail - Market size and forecast 2025-2030 ($ million); Chart on Retail - Year-over-year growth 2025-2030 (%); Data Table on Retail - Year-over-year growth 2025-2030 (%); 9.5 Online - Market size and forecast 2025-2030; Chart on Online - Market size and forecast 2025-2030 ($ million); Data Table on Online - Market size and forecast 2025-2030 ($ million); Chart on Online - Year-over-year growth 2025-2030 (%); Data Table on Online - Year-over-year growth 2025-2030 (%); 9.6 Market opportunity by End-user; Market opportunity by End-user ($ million); Data Table on Market opportunity by End-user ($ million)
10 Market Segmentation by Route of Administration
10 Market Segmentation by Route of Administration: 10.1 Market segments; Chart on Route of Administration - Market share 2025-2030 (%); Data Table on Route of Administration - Market share 2025-2030 (%); 10.2 Comparison by Route of Administration; Chart on Comparison by Route of Administration; Data Table on Comparison by Route of Administration; 10.3 Oral - Market size and forecast 2025-2030; Chart on Oral - Market size and forecast 2025-2030 ($ million); Data Table on Oral - Market size and forecast 2025-2030 ($ million); Chart on Oral - Year-over-year growth 2025-2030 (%); Data Table on Oral - Year-over-year growth 2025-2030 (%); 10.4 Injectable - Market size and forecast 2025-2030; Chart on Injectable - Market size and forecast 2025-2030 ($ million); Data Table on Injectable - Market size and forecast 2025-2030 ($ million); Chart on Injectable - Year-over-year growth 2025-2030 (%); Data Table on Injectable - Year-over-year growth 2025-2030 (%); 10.5 Nasal - Market size and forecast 2025-2030; Chart on Nasal - Market size and forecast 2025-2030 ($ million); Data Table on Nasal - Market size and forecast 2025-2030 ($ million); Chart on Nasal - Year-over-year growth 2025-2030 (%); Data Table on Nasal - Year-over-year growth 2025-2030 (%); 10.6 Market opportunity by Route of Administration; Market opportunity by Route of Administration ($ million); Data Table on Market opportunity by Route of Administration ($ million)
11 Customer Landscape
11 Customer Landscape: 11.1 Customer landscape overview; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
12 Geographic Landscape: 12.1 Geographic segmentation; Chart on Market share by geography - 2025-2030 (%); Data Table on Market share by geography - 2025-2030 (%); 12.2 Geographic comparison; Chart on Geographic comparison; Data Table on Geographic comparison; 12.3 Mexico - Market size and forecast 2025-2030; Chart on Mexico - Market size and forecast 2025-2030 ($ million); Data Table on Mexico - Market size and forecast 2025-2030 ($ million); Chart on Mexico - Year-over-year growth 2025-2030 (%); Data Table on Mexico - Year-over-year growth 2025-2030 (%); 12.4 Brazil - Market size and forecast 2025-2030; Chart on Brazil - Market size and forecast 2025-2030 ($ million); Data Table on Brazil - Market size and forecast 2025-2030 ($ million); Chart on Brazil - Year-over-year growth 2025-2030 (%); Data Table on Brazil - Year-over-year growth 2025-2030 (%); 12.5 Argentina - Market size and forecast 2025-2030; Chart on Argentina - Market size and forecast 2025-2030 ($ million); Data Table on Argentina - Market size and forecast 2025-2030 ($ million); Chart on Argentina - Year-over-year growth 2025-2030 (%); Data Table on Argentina - Year-over-year growth 2025-2030 (%); 12.6 Chile - Market size and forecast 2025-2030; Chart on Chile - Market size and forecast 2025-2030 ($ million); Data Table on Chile - Market size and forecast 2025-2030 ($ million); Chart on Chile - Year-over-year growth 2025-2030 (%); Data Table on Chile - Year-over-year growth 2025-2030 (%); 12.7 Rest of Latin America - Market size and forecast 2025-2030; Chart on Rest of Latin America - Market size and forecast 2025-2030 ($ million); Data Table on Rest of Latin America - Market size and forecast 2025-2030 ($ million); Chart on Rest of Latin America - Year-over-year growth 2025-2030 (%); Data Table on Rest of Latin America - Year-over-year growth 2025-2030 (%); 12.8 Market opportunity by geography; Market opportunity by geography ($ million); Data Table on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
13 Drivers, Challenges, and Opportunity: 13.1 Market drivers; Escalating disease prevalence and heightened public awareness; Modernization and infrastructure development; Technological innovation and rise in biological therapies; 13.2 Market challenges; Regulatory complexity and fragmented compliance standards; Economic instability and healthcare resource disparities; Insufficient medical specialization and diagnostic limitations; 13.3 Impact of drivers and challenges; Impact of drivers and challenges in 2025 and 2030; 13.4 Market opportunities; Proliferation of calcitonin gene-related peptide antagonists and targeted biologics; Integration of digital health ecosystems and personalized telemedicine; Increased awareness through WHO initiatives and local programs
14 Competitive Landscape
14 Competitive Landscape: 14.1 Overview; 14.2 Competitive Landscape; Overview on criticality of inputs and factors of differentiation; 14.3 Landscape disruption; Overview on factors of disruption; 14.4 Industry risks; Impact of key risks on business
15 Competitive Analysis
15 Competitive Analysis: 15.1 Companies profiled; Companies covered; 15.2 Company ranking index; Company ranking index; 15.3 Market positioning of companies; Matrix on companies position and classification; 15.4 AbbVie Inc.; AbbVie Inc. - Overview; AbbVie Inc. - Product / Service; AbbVie Inc. - Key news; AbbVie Inc. - Key offerings; SWOT; 15.5 Amgen Inc.; Amgen Inc. - Overview; Amgen Inc. - Product / Service; Amgen Inc. - Key news; Amgen Inc. - Key offerings; SWOT; 15.6 Amneal Pharmaceuticals Inc.; Amneal Pharmaceuticals Inc. - Overview; Amneal Pharmaceuticals Inc. - Business segments; Amneal Pharmaceuticals Inc. - Key news; Amneal Pharmaceuticals Inc. - Key offerings; Amneal Pharmaceuticals Inc. - Segment focus; SWOT; 15.7 Bausch Health Companies Inc.; Bausch Health Companies Inc. - Overview; Bausch Health Companies Inc. - Business segments; Bausch Health Companies Inc. - Key news; Bausch Health Companies Inc. - Key offerings; Bausch Health Companies Inc. - Segment focus; SWOT; 15.8 Bayer AG; Bayer AG - Overview; Bayer AG - Business segments; Bayer AG - Key news; Bayer AG - Key offerings; Bayer AG - Segment focus; SWOT; 15.9 Daiichi Sankyo Co. Ltd.; Daiichi Sankyo Co. Ltd. - Overview; Daiichi Sankyo Co. Ltd. - Business segments; Daiichi Sankyo Co. Ltd. - Key offerings; Daiichi Sankyo Co. Ltd. - Segment focus; SWOT; 15.10 Dr Reddys Laboratories Ltd.; Dr Reddys Laboratories Ltd. - Overview; Dr Reddys Laboratories Ltd. - Business segments; Dr Reddys Laboratories Ltd. - Key news; Dr Reddys Laboratories Ltd. - Key offerings; Dr Reddys Laboratories Ltd. - Segment focus; SWOT; 15.11 Eli Lilly and Co.; Eli Lilly and Co. - Overview; Eli Lilly and Co. - Product / Service; Eli Lilly and Co. - Key offerings; SWOT; 15.12 GlaxoSmithKline Plc; GlaxoSmithKline Plc - Overview; GlaxoSmithKline Plc - Business segments; GlaxoSmithKline Plc - Key news; GlaxoSmithKline Plc - Key offerings; GlaxoSmithKline Plc - Segment focus; SWOT; 15.13 H. Lundbeck A/S; H. Lundbeck A/S - Overview; H. Lundbeck A/S - Product / Service; H. Lundbeck A/S - Key offerings; SWOT; 15.14 Mallinckrodt Plc; Mallinckrodt Plc - Overview; Mallinckrodt Plc - Business segments; Mallinckrodt Plc - Key news; Mallinckrodt Plc - Key offerings; Mallinckrodt Plc - Segment focus; SWOT; 15.15 Pfizer Inc.; Pfizer Inc. - Overview; Pfizer Inc. - Product / Service; Pfizer Inc. - Key news; Pfizer Inc. - Key offerings; SWOT; 15.16 Sanofi SA; Sanofi SA - Overview; Sanofi SA - Business segments; Sanofi SA - Key news; Sanofi SA - Key offerings; Sanofi SA - Segment focus; SWOT; 15.17 Teva Pharmaceutical Ltd.; Teva Pharmaceutical Ltd. - Overview; Teva Pharmaceutical Ltd. - Business segments; Teva Pharmaceutical Ltd. - Key news; Teva Pharmaceutical Ltd. - Key offerings; Teva Pharmaceutical Ltd. - Segment focus; SWOT; 15.18 UCB SA; UCB SA - Overview; UCB SA - Product / Service; UCB SA - Key offerings; SWOT
16 Appendix
16 Appendix: 16.1 Scope of the report; Market definition; Objectives; Notes and caveats; 16.2 Inclusions and exclusions checklist; Inclusions checklist; Exclusions checklist; 16.3 Currency conversion rates for US$; Currency conversion rates for US$; 16.4 Research methodology; Research methodology; 16.5 Data procurement; Information sources; 16.6 Data validation; Data validation; 16.7 Validation techniques employed for market sizing; Validation techniques employed for market sizing; 16.8 Data synthesis; Data synthesis; 16.9 360 degree market analysis; 360 degree market analysis; 16.10 List of abbreviations; List of abbreviations; Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Country Market Characteristics; Exhibits4: Executive Summary - Chart on Market by Geography; Exhibits5: Executive Summary - Chart on Market Segmentation by Therapy; Exhibits6: Executive Summary - Chart on Market Segmentation by End-user; Exhibits7: Executive Summary - Chart on Market Segmentation by Route of Administration; Exhibits8: Executive Summary - Chart on Incremental Growth; Exhibits9: Executive Summary - Data Table on Incremental Growth; Exhibits10: Executive Summary - Chart on Company Market Positioning; Exhibits11: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits12: Overview on criticality of inputs and factors of differentiation; Exhibits13: Overview on factors of disruption; Exhibits14: Impact of drivers and challenges in 2025 and 2030; Exhibits15: Chart on Parent Market; Exhibits16: Data Table on - Parent Market; Exhibits17: Chart on Market characteristics analysis; Exhibits18: Chart on Value chain analysis; Exhibits19: Data Table on Offerings of companies included in the market definition; Exhibits20: Market segments; Exhibits21: Chart on Latin America - Market size and forecast 2025-2030 ($ million); Exhibits22: Data Table on Regional - Market size and forecast 2025-2030 ($ million); Exhibits23: Chart on Latin America: Year-over-year growth 2025-2030 (%); Exhibits24: Data Table on Regional - Market size and forecast 2025-2030 ($ million); Exhibits25: Historic Market Size - Data Table on Migraine Drugs Market in Latin America 2020 - 2024 ($ million); Exhibits26: Historic Market Size - Therapy Segment 2020 - 2024 ($ million); Exhibits27: Historic Market Size - End-user Segment 2020 - 2024 ($ million); Exhibits28: Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million); Exhibits29: Historic Market Size - Geography Segment 2020 - 2024 ($ million); Exhibits30: Five forces analysis - Comparison between 2025 and 2030; Exhibits31: Bargaining power of buyers - Impact of key factors 2025 and 2030; Exhibits32: Bargaining power of suppliers - Impact of key factors in 2025 and 2030; Exhibits33: Threat of new entrants - Impact of key factors in 2025 and 2030; Exhibits34: Threat of substitutes - Impact of key factors in 2025 and 2030; Exhibits35: Threat of rivalry - Impact of key factors in 2025 and 2030; Exhibits36: Chart on Market condition - Five forces 2025 and 2030; Exhibits37: Chart on Therapy - Market share 2025-2030 (%); Exhibits38: Data Table on Therapy - Market share 2025-2030 (%); Exhibits39: Chart on Comparison by Therapy; Exhibits40: Data Table on Comparison by Therapy; Exhibits41: Chart on Preventive treatment - Market size and forecast 2025-2030 ($ million); Exhibits42: Data Table on Preventive treatment - Market size and forecast 2025-2030 ($ million); Exhibits43: Chart on Preventive treatment - Year-over-year growth 2025-2030 (%); Exhibits44: Data Table on Preventive treatment - Year-over-year growth 2025-2030 (%); Exhibits45: Chart on Abortive treatment - Market size and forecast 2025-2030 ($ million); Exhibits46: Data Table on Abortive treatment - Market size and forecast 2025-2030 ($ million); Exhibits47: Chart on Abortive treatment - Year-over-year growth 2025-2030 (%); Exhibits48: Data Table on Abortive treatment - Year-over-year growth 2025-2030 (%); Exhibits49: Market opportunity by Therapy ($ million)

Search Inside Report

Pricing

Currency Rates

Single User Online Download $2,500
Global Site License Online Download $4,000

How Do Licenses Work?

Request A Sample

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now